

DESCRIPTION

Species Reactivity	Human/Cynomolgus Monkey
Specificity	Detects human FCAR/CD89 in direct ELISAs. Detects human and cynomolgus monkey FCAR/CD89 in Flow cytometry. In direct ELISAs, no cross-reactivity with Fcγ RIA, RIIA, or RIIIB is observed.
Source	Monoclonal Mouse IgG ₁ Clone # 488032
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	NS0 mouse myeloma cell line transfected with human FCAR/CD89 Gln22-Lys287 Accession # P24071
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Human blood-derived granulocytes and HEK293 human cell line transfected with Cynomolgus FCAR/CD89 and eGFP

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

FCAR, also called FcαRI or CD89, is a variably glycosylated 50-100 kDa myeloid-specific type I transmembrane (TM) Fc receptor for IgA that is a member of the multichain immune recognition receptor (MIRR) family (1-3). Human FCAR contains a 21 amino acid (aa) signal sequence and extracellular (ECD), TM and cytoplasmic domains of 206, 19 and 41 aa, respectively (4). Arg230 within the TM domain supports interaction with the ITAM-containing signaling subunit, FcRγ, which contains a TM Asp (5-7). Two ECD C2-type Ig-like domains (EC1 and 2) are oriented at right angles (8). Up to two molecules of FCAR can bind one molecule of serum IgA via EC1 (8). Many splice variants have been reported, but only two have been identified as proteins (9, 10). The a.2 form, which lacks 22 aa just prior to the TM domain, is exclusively expressed in alveolar macrophages. The a.3 form lacks EC2. FCAR binds monomeric, polymeric and secretory IgA, but does not mediate the barrier function of secretory IgA in mucosal epithelium (1-3). Shedding and circulation of polymeric IgA/FCAR immune complexes has been reported (11). Circulating neutrophils, eosinophils, and monocytes express FCAR (12). Tissue expression of FCAR is mainly from neutrophils; FCAR is downregulated as monocytes differentiate to tissue macrophages (12). On neutrophils, a significant amount of FCAR lacks FcRγ, but can still be endocytosed to early endosomes and recycled to the cell surface (5). Binding of serum IgA to FCAR is transient and anti-inflammatory, inhibiting IgG or IgE-induced degranulation (6). Sustained aggregation of FCAR results in inflammatory responses (6). FcRγ signaling is required for these and for transport to late endosomes (5-7). Human FCAR shows 55-58% aa identity with rat, horse and cow FCAR. No ortholog occurs in mouse. FCAR structure resembles the KIR/ILT/LIR/MIR family more than other IgA receptors, including plgR, Fcα/µR, asialoglycoprotein receptor (ASGR1) and transferrin receptor (TfR) (1-3).

References:

1. Wines, B. D. and P. M. Hogarth (2006) *Tissue Antigens* **68**:103.
2. Otten, M. A. and M. van Egmon (2004) *Immunol. Lett.* **92**:23.
3. Montiero, R. C. and J. G. J. van de Winkel (2003) *Annu. Rev. Immunol.* **21**:177.
4. Maliszewski, C. R. *et al.* (1990) *J. Exp. Med.* **172**:1665.
5. Launay, P. *et al.* (1999) *J. Biol. Chem.* **274**:7216.
6. Pasquier, B. *et al.* (2005) *Immunity* **22**:31.
7. Shen, L. *et al.* (2001) *Blood* **97**:205.
8. Herr, Y. *et al.* (2003) *Nature* **423**:614.
9. Patry, C. *et al.* (1996) *J. Immunol.* **156**:4442.
10. Togo, S. *et al.* (2003) *FEBS Lett.* **535**:205.
11. van der Boog, P. J. M. *et al.* (2002) *J. Immunol.* **168**:1252.
12. Hamre, R. *et al.* (2003) *Scand. J. Immunol.* **57**:506.

Human/Cynomolgus Monkey FCAR/CD89 Alexa Fluor® 750-conjugated Antibody

Monoclonal Mouse IgG₁ Clone # 488032

Catalog Number: FAB3939S

100 µg

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.